Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 229 to 232 of 232 entries
Sorted by: Best Match Show Resources per page
Successful glucose lowering therapy triumphs in heart failure.

EClinicalMedicine

Rossing P.
PMID: 34235416
EClinicalMedicine. 2021 Jun 26;37:100996. doi: 10.1016/j.eclinm.2021.100996. eCollection 2021 Jul.

No abstract available.

Cite
Rossing P. Successful glucose lowering therapy triumphs in heart failure. EClinicalMedicine. 2021;37:100996doi: 10.1016/j.eclinm.2021.100996.
Rossing, P. (2021). Successful glucose lowering therapy triumphs in heart failure. EClinicalMedicine, 37100996. https://doi.org/10.1016/j.eclinm.2021.100996
Rossing, Peter. "Successful glucose lowering therapy triumphs in heart failure." EClinicalMedicine vol. 37 (2021): 100996. doi: https://doi.org/10.1016/j.eclinm.2021.100996
Rossing P. Successful glucose lowering therapy triumphs in heart failure. EClinicalMedicine. 2021 Jun 26;37:100996. doi: 10.1016/j.eclinm.2021.100996. eCollection 2021 Jul. PMID: 34235416; PMCID: PMC8250160.
Copy Download .nbib Format: NLM
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

The New England journal of medicine

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM.
PMID: 34449181
N Engl J Med. 2021 Dec 09;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.

BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in...

Cite
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263doi: 10.1056/NEJMoa2110956.
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine, 385(24), 2252-2263. https://doi.org/10.1056/NEJMoa2110956
Pitt, Bertram, et al. "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes." The New England journal of medicine vol. 385,24 (2021): 2252-2263. doi: https://doi.org/10.1056/NEJMoa2110956
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 09;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.
Copy Download .nbib Format: NLM
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Circulation

Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL.
PMID: 33198491
Circulation. 2021 Feb 09;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.

BACKGROUND: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease and...

Cite
Filippatos G, Anker SD, Agarwal R, et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2020;143(6):540-552doi: 10.1161/CIRCULATIONAHA.120.051898.
Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., Bakris, G. L. (2021). Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 143(6), 540-552. https://doi.org/10.1161/CIRCULATIONAHA.120.051898
Filippatos, Gerasimos, et al. "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes." Circulation vol. 143,6 (2021): 540-552. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051898
Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 09;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. PMID: 33198491; PMCID: PMC7864612.
Copy Download .nbib Format: NLM
Protein phosphatase 4 controls circadian clock dynamics by modulating CLOCK/BMAL1 activity.

Genes & development

Klemz S, Wallach T, Korge S, Rosing M, Klemz R, Maier B, Fiorenza NC, Kaymak I, Fritzsche AK, Herzog ED, Stanewsky R, Kramer A.
PMID: 34301769
Genes Dev. 2021 Aug 01;35(15):1161-1174. doi: 10.1101/gad.348622.121. Epub 2021 Jul 22.

In all organisms with circadian clocks, post-translational modifications of clock proteins control the dynamics of circadian rhythms, with phosphorylation playing a dominant role. All major clock proteins are highly phosphorylated, and many kinases have been described to be responsible....

Cite
Klemz S, Wallach T, Korge S, et al. Protein phosphatase 4 controls circadian clock dynamics by modulating CLOCK/BMAL1 activity. Genes Dev. 2021;35(15):1161-1174doi: 10.1101/gad.348622.121.
Klemz, S., Wallach, T., Korge, S., Rosing, M., Klemz, R., Maier, B., Fiorenza, N. C., Kaymak, I., Fritzsche, A. K., Herzog, E. D., Stanewsky, R., & Kramer, A. (2021). Protein phosphatase 4 controls circadian clock dynamics by modulating CLOCK/BMAL1 activity. Genes & development, 35(15), 1161-1174. https://doi.org/10.1101/gad.348622.121
Klemz, Sabrina, et al. "Protein phosphatase 4 controls circadian clock dynamics by modulating CLOCK/BMAL1 activity." Genes & development vol. 35,15 (2021): 1161-1174. doi: https://doi.org/10.1101/gad.348622.121
Klemz S, Wallach T, Korge S, Rosing M, Klemz R, Maier B, Fiorenza NC, Kaymak I, Fritzsche AK, Herzog ED, Stanewsky R, Kramer A. Protein phosphatase 4 controls circadian clock dynamics by modulating CLOCK/BMAL1 activity. Genes Dev. 2021 Aug 01;35(15):1161-1174. doi: 10.1101/gad.348622.121. Epub 2021 Jul 22. PMID: 34301769; PMCID: PMC8336894.
Copy Download .nbib Format: NLM
Showing 229 to 232 of 232 entries